Baidu
map

Vision Res. :糖尿病视网膜病变,代谢记忆和表观遗传修饰

2017-07-15 cuiguizhong MedSci原创

底特律韦恩州立大学Kresge眼科研究所的Kowluru RA教授在近期的Vision Res杂志上发表了一项工作,对糖尿病视网膜病变中代谢记忆和表观遗传修饰现象进行了讨论。

底特律韦恩州立大学Kresge眼科研究所的Kowluru RA教授在近期的Vision Res杂志上发表了一项工作,对糖尿病视网膜病变中代谢记忆和表观遗传修饰现象进行了讨论。

视网膜病是一种威胁眼睛视力的疾病,同时也是糖尿病最可怕的并发症之一。高血糖是糖尿病性视网膜病变的主要发病诱因,经过治疗,虽然糖尿病患者可以重新正常控制血糖,但糖尿病视网膜病变的主要发病进程仍然存在。高血糖对机体造成的损伤取决于高血糖的持续时间和严重程度,提示存在"代谢记忆"现象。

代谢记忆现象在糖尿病视网膜病变实验模型中成功重现。高血糖除了引发许多生物化学和功能异常、改变与其相关基因的表达外,还增加了氧化应激反应。细胞质活性氧的增加造成线粒体功能障碍。受损的抗氧化防御系统对于中和自由基变得不堪重负。随着糖尿病持续时间的延长,线粒体DNA(mtDNA)受到损伤,进而引起mtDNA编码的在电子传递链中具有重要的蛋白质受到影响。这导致自由基的"自我扩增"恶性循环,使得视网膜病进一步发展。

高血糖也影响负责表观遗传修饰的酶;这些修饰改变基因表达而不影响DNA序列。许多酶的组蛋白和DNA修饰在线粒体内环境稳定中具有重要作用,高血糖影响其活性并阻碍线粒体内环境稳定。实验显示,在大鼠糖尿病(链脲佐菌素)模型中,只有当大鼠重新维持正常血糖,这些表观遗传修饰才有可能停止。但如果在向正常血糖转化前几个月高血糖依然存在,则这些表观遗传学修饰仍然会发生。在正常葡萄糖阶段向高葡萄糖耐受的转化过程中,靶向治疗的目标是防止增加的氧化应激反应或表观遗传修饰,这有助于改善这些异常并防止糖尿病视网膜病变的进展。

因此,他们认为在不干扰糖尿病患者对血糖控制的情况下,用靶向治疗作为补充,到达"最佳"血糖控制,这有可能阻止该致盲疾病的进一步发展。这项工作给糖尿病视网膜病变的治疗带来了新的思路。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
    2017-07-16 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
    2017-07-16 zhangyxzsh
  5. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
    2017-07-15 有备才能无患

    尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
    2017-07-15 Y—xianghai

    学习了新知识学习了新知识学习了新知识

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
    2017-07-15 135****7952平儿

    学了。。。。。。。。。。。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2075641, encodeId=6bb720e56419e, content=<a href='/topic/show?id=afce902528d' target=_blank style='color:#2F92EE;'>#表观遗传修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90252, encryptionId=afce902528d, topicName=表观遗传修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Fri Jul 28 07:53:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269909, encodeId=78b61269909cd, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413894, encodeId=913d141389448, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569292, encodeId=8e6a15692927c, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Jul 16 21:53:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222565, encodeId=1a6322256538, content=尽管视力结果有所改善,接受全身免疫抑制治疗的葡萄膜炎患者可能会在心理健康层面上出现恶化。这项工作,对于患者是否进行葡萄膜炎的治疗提供参考。, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sat Jul 15 11:23:51 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222475, encodeId=2d7b2224e597, content=学习了新知识学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Jul 15 08:24:04 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222465, encodeId=b85a2224653a, content=学了。。。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Sat Jul 15 07:45:02 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222450, encodeId=1534222450b6, content=好好看一下,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Jul 15 07:27:44 CST 2017, time=2017-07-15, status=1, ipAttribution=)]
    2017-07-15 忠诚向上

    好好看一下,继续学习

    0

相关资讯

JAMA Ophthalmol:富含ω-3脂肪酸的饮食可显著降低糖尿病视网膜病变的发病率

据发表于JAMA Ophthalmol的一项前瞻性观察研究显示,摄入ω3脂肪酸的老年2型糖尿病患者与食用两星期鱼油效果一样可显著降低糖尿病视网膜病变的发病风险。 糖尿病视网膜病变是导致老年人视力丧失的主要原因。其发病机制尚不完全清楚,但炎症、氧化应激和微血管改变在视网膜功能恶化中起着重要作用。视网膜中长链ω3多不饱和脂肪酸的含量很高,而长链ω3多不饱和脂肪酸形成oxylipins,具有抗炎和

Lancet子刊:meta分析显示ACEI类RAS抑制剂在糖尿病视网膜病变中获益更大

最近的一些研究结果陆续表明肾素-血管紧张素系统( RAS)抑制剂对糖尿病性视网膜病变具有潜在的受益价值,但不同学者这一研究结果仍存在争议。《Lancet》最近刊登了一篇中国学者做的系统回顾和荟萃分析来评估RAS抑制剂对糖尿病性视网膜病变的影响。科研人员搜索采集来自自PubMed、Embase Cochrane图书馆主要注册的对照试验,及重要年度会议摘要。研究者将满足随机对照原则并且是比较血管紧张素

Diabetologia:强化血糖控制对糖尿病视网膜病变有双向影响

临床试验表明高血糖对糖尿病患者微血管并发症发生和发展有不利影响,因此,当前血糖控制中仍有糖尿病微血管并发症的基础治疗。同时,良好的血糖控制已被证明可降低新诊断2型糖尿病患者糖尿病视网膜病变的进展。然而,在病程长、而血糖控制欠佳的2型糖尿病患者中,这方面的研究数据较少。 为此,来自美国Jr VA医院的Azad教授及其团队进行了一项研究,探讨血糖控制欠佳的糖尿病患者中,强化血糖控制(INT)

FDA批准阿柏西普治疗DR合并DME

近日,FDA批准(Eylea)阿柏西普注射剂,可用于糖尿病黄斑水肿(DME)合并糖尿病视网膜病变(DR)的治疗。糖尿病视网膜病变(DR)是最常见糖尿病眼部疾病,是美国成年人中致盲的首要疾病。根据美国疾病控制与防范中心的调查,糖尿病(包括I型与2型)已经危及全美2900万人,在20-74岁的成人中,DR是新的最常见的致盲疾病。在2008年,有33%成年糖尿病患者在40岁或以上出现DR。在一些DR合并

PLoS One:血清高甘露糖结合凝集素的水平与国人2型糖尿病患者糖尿病视网膜病变有关

PLoS One:血清高甘露糖结合凝集素的水平与国人2型糖尿病患者糖尿病视网膜病变有关该研究的目的是为了探究伴或不伴糖尿病视网膜病变(DR)的2型糖尿病患者血清中甘露糖结合凝集素(MBL)的水平。测定324名2型糖尿病患者以及300名健康对照者血清中MBL的水平。采用多元回归模型进行多因素分析。使用接受者操作特性曲线测试MBL以及其他标志物的总体预测精确度。结果发现,伴DR的糖尿病患者以及伴威胁视

JAMA Ophthalmol:低剂量多西环素可延缓糖尿病网膜病变

大多数糖尿病患者都会受到糖尿病视网膜病变(DR)的困扰,目前尚无能延缓非增值性DR的简便有效治疗方法。血管内皮生长因子抑制剂虽可延缓DR的进展,但却未被广泛应用,且需要多次眼内注射。  为探讨多西环素对DR是否具有延缓作用,美国及丹麦研究者开展了一项为期24个月的小型概念验证性随机、双盲研究。结果显示,低剂量多西环素可延缓DR的进展。研究者宾夕法尼亚州立大学医学院赫尔希眼科中心及公共卫生部的Ing

Baidu
map
Baidu
map
Baidu
map